ALKS vs. MDGL, FOLD, IONS, GERN, AGIO, LGND, DVAX, PCRX, MNKD, and IRWD
Should you be buying Alkermes stock or one of its competitors? The main competitors of Alkermes include Madrigal Pharmaceuticals (MDGL), Amicus Therapeutics (FOLD), Ionis Pharmaceuticals (IONS), Geron (GERN), Agios Pharmaceuticals (AGIO), Ligand Pharmaceuticals (LGND), Dynavax Technologies (DVAX), Pacira BioSciences (PCRX), MannKind (MNKD), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "pharmaceutical preparations" industry.
Madrigal Pharmaceuticals (NASDAQ:MDGL) and Alkermes (NASDAQ:ALKS) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, community ranking and risk.
98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 23.9% of Madrigal Pharmaceuticals shares are held by insiders. Comparatively, 4.9% of Alkermes shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Madrigal Pharmaceuticals presently has a consensus price target of $345.09, suggesting a potential upside of 56.82%. Alkermes has a consensus price target of $35.38, suggesting a potential upside of 46.48%. Given Alkermes' stronger consensus rating and higher possible upside, research analysts plainly believe Madrigal Pharmaceuticals is more favorable than Alkermes.
Madrigal Pharmaceuticals has a beta of -0.33, suggesting that its stock price is 133% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500.
Alkermes has a net margin of 25.17% compared to Alkermes' net margin of 0.00%. Madrigal Pharmaceuticals' return on equity of 20.31% beat Alkermes' return on equity.
Alkermes received 235 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. Likewise, 70.69% of users gave Alkermes an outperform vote while only 68.60% of users gave Madrigal Pharmaceuticals an outperform vote.
Alkermes has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.
In the previous week, Madrigal Pharmaceuticals had 7 more articles in the media than Alkermes. MarketBeat recorded 12 mentions for Madrigal Pharmaceuticals and 5 mentions for Alkermes. Madrigal Pharmaceuticals' average media sentiment score of 1.30 beat Alkermes' score of -0.29 indicating that Alkermes is being referred to more favorably in the news media.
Summary
Alkermes beats Madrigal Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding ALKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alkermes Competitors List
Related Companies and Tools
